Celltrion

This phase 3 trial tests whether a new drug called CT-P51 works as well as the established immunotherapy Keytruda for people with advanced non-squamous non-small cell lung cancer that has not been treated before. All participants also receive standard chemotherapy. The study comp…

This study is observing about 881 people with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, or psoriasis who are taking Remsima (a biologic drug) either as a shot under the skin or through an IV. The goal is to track any serious side effects over time. Resear…

This phase 3 trial tests whether CT-P55, a biosimilar of secukinumab, works as well as the approved drug Cosentyx for moderate to severe plaque psoriasis. 153 adults with chronic psoriasis for at least 6 months are receiving either CT-P55 or Cosentyx injections. The main goal is …

This study tests whether a new biosimilar medicine (CT-P52) works similarly to the approved drug Taltz in the body. It involves 218 healthy adults aged 19 to 55 who receive a single dose of either the biosimilar or Taltz. The main goal is to compare how the drug is absorbed and i…